Rapid Dose Therapeutics Fiscal Year 2024 Financial Results Showcase Impressive Revenue Surge

Tuesday, 2 July 2024, 11:23
Rapid Dose Therapeutics released their fiscal year 2024 financial results, reporting a notable 41.7% year-over-year increase in revenue to reach C$1.02M. Despite a negative GAAP EPS of -C$0.04, the company demonstrates robust performance highlighted by significant revenue growth.
LivaRava Finance Meta Image
Rapid Dose Therapeutics Fiscal Year 2024 Financial Results Showcase Impressive Revenue Surge

Rapid Dose Therapeutics FY2024 Financial Results

Rapid Dose Therapeutics recently disclosed their financial performance for the fiscal year 2024, revealing a remarkable 41.7% surge in revenue to achieve C$1.02M.

GAAP EPS and Revenue Figures

The company disclosed a GAAP EPS of -C$0.04 alongside the revenue statistic, showcasing substantial growth in the reported period.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe